NCT01316718已完成4 期
Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D).
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 108
- 试验地点
- 1
- 主要终点
- Change from baseline of number of mast cell per mm2 at week 12
研究概览
简要总结
The purpose of the trial is to define the clinical benefit and possible mediators of the benefit of mesalazine in Irritable Bowel Syndrome (IBS) with diarrhoea.
The investigators will therefore evaluate symptoms (primarily bowel frequency) and markers reflecting mast cell activation and small bowel tone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or Female patients aged 18-75 years old able to give informed consent.
- •Patients should all have had a colonoscopy or a sigmoidoscopy within the last 12 months to exclude microscopic colitis. (If not, but they have had a negative colonoscopy within 5 years and symptoms are unchanged, then a sigmoidoscopy and mucosal biopsy of the left colon would be sufficient to exclude microscopic colitis).
- •IBS-D Patients meeting Rome III criteria prior to screening phase.
- •Patients with ≥ 25% soft (score > 4) and < 25% hard (score 1 or 2) stools during the screening phase, as scored by the daily symptom and stool diary*.
- •Patients with a stool frequency of 3 or more per day for 2 or more days per week during the screening phase*.
- •Satisfactory completion of the daily stool and symptom diary during the screening phase at the discretion of the investigator.
- •Women of child bearing potential willing or able to use at least one highly effective contraceptive method throughout the study. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly such as: implants, injectables, combined oral contraceptives, sexual abstinence or vasectomised partner.
- •If inclusion criterion 4 and/or 5 is/are not met but the results are considered atypical (as observed from medical history and patient recall) then the patient can be re-screen on 1 occasion only.
排除标准
- •Women who are pregnant or breast feeding
- •Prior abdominal surgery which may cause bowel symptoms similar to IBS (note appendectomy and cholecystectomy will not be an exclusion)
- •Patients unable to stop anti-muscarinics, anti-spasmodics, high dose tricyclic antidepressants (i.e. above 50 mg/day), opiates/anti-diarrhoeal drugs*, NSAIDs (occasional over the counter use and topical formulations are allowed), long-term antibiotics, other anti-inflammatory drugs or 5-ASA containing drugs.
- •Patients on selective serotonin re-uptake inhibitors and low dose tricyclic antidepressants (i.e. up to 50 mg/day) for at least 3 months previous unwilling to remain on a stable dose for the duration of the trial.
- •Patients with other gastro-intestinal diseases including colitis and Crohn's disease.
- •Patients with the following conditions: Renal impairment, severe hepatic impairment or salicylate hypersensitivity.
- •Patients currently participating in another trial or have been in a trial within the previous 3 months
- •Patients who in the opinion of the investigator are considered unsuitable due to inability to comply with instructions
- •Patients with serious concomitant diseases e.g. cardiovascular, respiratory, neurological etc.
- •Loperamide is allowed as rescue medication through-out the trial, however if > 2 doses / week are taken during the screening phase then they are not eligible, though they can be re-screened on 1 occasion only.
研究组 & 干预措施
Mesalazine Granules
Experimental
2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
干预措施: Mesalazine (Drug)
Placebo Granules
Placebo Comparator
2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline of number of mast cell per mm2 at week 12
时间窗: Week 0 and week 12
Mechanistic endpoint
Change from baseline in average stool frequency during weeks 11 and 12.
时间窗: Week 0 and week 12
Clinical Endpoint
次要结局
- Average daily severity of abdominal pain on a 0-10 scale(Week 0 to week 12)
- Days with urgency(weeks 11-12)
- Mean stool consistency using Bristol Stool Form Score(Week 0 to week 12)
- Mast cell tryptase release during 6 hour biopsy incubation(Week 0 and week 12)
- IL-1β, TNF-a, histamine and serotonin secretion during same incubation(Week 0 and week 12)
- Small bowel tone assessed by volume of fasting small bowel water(Week 0 and week 12)
- Euro-Qol Score(Week 0 and week 12)
- Centres for disease control and prevention health related quality of life healthy days core module score(Week 0 and week 12)
- Hospital Anxiety Depression Scale Score(Week 0 and week 12)
- Patient Health Questionnaire -15(Week 0 and week 12)
- Global satisfaction with control of IBS symptoms(Week 0 to week 12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Mesalazine for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D)Irritable bowel syndromeISRCTN76612274niversity of Nottingham (UK)108
进行中（未招募）
1 期
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). - Mesalazine for the treatment of IBS-DDiarrhoea-predominant irritable bowel syndromeMedDRA version: 14.0 Level: LLT Classification code 10060849 Term: Diarrhoea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-018340-14-GBniversity of Nottingham136
已完成
3 期
Mesalazine Therapy in Patients With Irritable Bowel SyndromeIrritable Bowel SyndromeNCT00626288SOFAR S.p.A.187
进行中（未招募）
不适用
Evaluation of the role of mesalazine in the treatment of diverticular disease of the colon and irritable colon syndrome: A randomised double blind placebo controlled clinical study - NDIrritable bowel Syndrome Diverticular disease of the colonMedDRA version: 9.1Level: LLTClassification code 10009993MedDRA version: 9.1Level: LLTClassification code 10023004EUCTR2008-004228-22-ITSOFAR SPA
终止
3 期
Mesalazine Granules vs. Placebo for the Prevention of Recurrence of DiverticulitisDiverticulitisNCT00695643Dr. Falk Pharma GmbH345